Arianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
‘Bridgerton’ Fans Paid Hundreds To Attend A Regency-Era Ball Based On The Show—Now They Say It Was A ‘Scam’ Alex Jones’ Infowars Will Be Auctioned Off To Help Pay Sandy Hook Families $1.5 Billion—Here’s What To Know Ozempic may lower the risk of opioid overdose in patients with Type 2 diabetes, a new study suggests, the latest research to find a positive connection between the diabetes drug and another unrelated condition.
Some 3,000 participants with Type 2 diabetes and opioid use disorder were prescribed semaglutide and another 29,972 were prescribed other diabetic medications between December 2017 and December 2023, according to the study published Wednesday in JAMA Network Open.Semaglutide was associated with around a 60% decrease in opioid overdoses: There were 48 cases of opioid overdose in the group taking semaglutide, while there were 72 reports of overdose in the other participants.The JAMA researchers don’t know the connection between semaglutide and opioid use disorder, and believe further research is needed in order to understand it. Semaglutide was also found to help curb. Patients taking the drug with alcohol use disorder reported less urges to drink. Semaglutide is a part of a class of drugs called glucagon-like peptide-1 receptor agonists, and they’re used to treat diabetes and weight loss by interacting with the hunger part of the brain to suppress the appetite, and lowering blood sugar and A1C. The drugs also replicate the effects of the GLP-1 hormone, which is a part of the reward pathways in the brain that drive people to participate in pleasurable activities like eating food. That explains why the drugs help people lose weight, but researchers believe that might also explain the drugs’ effect on people with drug and alcohol use disorders,to Science Adviser. “Parts of the brain that drive eating behaviors overlap extensively with the drive to use alcohol or other substances,” Dr. Lorenzo Leggio and Dr. Leandro Vendruscolo, chief scientists with the National Institute on Alcohol Use and Alcoholism, and the National Institute on Drug Abuse,other diseases and disorders. After trials showed its drugs were successful at treating cardiovascular issues, Novo Nordisk successfully gained approval from the Food and Drug Administration in March to add cardiovascular benefits to Wegovy’s label. Eli Lilly—the maker of Zepbound and Mounjaro—said in May it was looking to add sleep apnea treatment to Zepbound’s label after a previous study found it improved sleep apnea symptoms. Other studies found the drugs can potentially treat brain and mood disorders like Alzheimers, Parkinson’s, depression, anxiety, suicide and bipolar disorder. Researchers also discovered GLP-1s may treat kidney disease, cancer, sleep apnea, high blood pressure and fatty liver disease. What To Know About Ozempic: The Diabetes Drug Becomes A Viral Weight Loss Hit Creating A ShortageOur community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.Insults, profanity, incoherent, obscene or inflammatory language or threats of any kindContinuous attempts to re-post comments that have been previously moderated/rejectedAttempts or tactics that put the site security at riskProtect your community.
GLP-1 Wegovy Semaglutide Weight Loss Drug Ozempic Drug Use Ozempic Opioid Use Ozempic Opioid Overdose Ozempic Opioid Use Disorder
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How Ozempic, Wegovy, Mounjaro, Zepbound May Help Treat Other Diseases: Here’s What To KnowArianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
Read more »
Women Taking Mounjaro And Zepbound Lose More Weight Than Men, New Study Suggests: What To KnowArianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
Read more »
“Nature’s Ozempic” Supplements May Not Live Up to the HypeNew supplements claiming to offer weight loss benefits similar to Ozempic and Wegovy, dubbed “nature’s Ozempic,” are hitting the market. However, experts warn that these products may not contain the same active ingredients or undergo the same rigorous testing as approved medications.
Read more »
Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study saysThe results suggest Ozempic could potentially become a new alternative treatment for opioid use disorder, which could help address the ongoing opioid epidemic.
Read more »
Ozempic May Decrease Opioid Overdose Risk In Certain PatientsA new study suggests that semaglutide, the active ingredient in Novo Nordisk's diabetes drug Ozempic, could potentially become a new alternative treatment for opioid use disorder. The data adds to growing evidence that GLP-1 drugs may have health benefits beyond regulating blood sugar and promoting weight loss.
Read more »
Ozempic May Reduce Opioid Overdose Risk In Certain PatientsA new study suggests that Novo Nordisk's blockbuster diabetes drug Ozempic, containing the active ingredient semaglutide, could potentially decrease the risk of opioid overdoses in patients diagnosed with both Type 2 diabetes and opioid use disorder. This finding adds to growing evidence that GLP-1 medications, a popular class used for diabetes and obesity treatment, may offer benefits beyond blood sugar regulation and weight loss.
Read more »